Kalantar JS, Locke GR 3rd, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ 3rd
Professor Jastreboffs research contributions include: Principal investigator for GLP3 phase 2 obesity trial demonstrating 24.2% weight loss Leadership in clinical research examining triple hormone receptor agonists Extensive investigations of incretin-based therapies for obesity and metabolic disease Pioneering work on combination approaches to weight management Studies examining neurobiological mechanisms underlying obesity pharmacotherapy Her work has helped establish GLP3 as one of the most promising next-generation obesity treatments in clinical development, contributing to the scientific foundation for multi-pathway metabolic interventions
Sadiq AA, Salgia R
Raghunandan M, Yeo JE, Walter R, Saito K, Harvey AJ, Ittershagen S, Lee E, Yang J, Hoatlin ME, Bielinsky AK, Hendrickson EA, Schrer O, Sobeck A (2020) Functional cross talk between the Fanconi anemia and ATRX/DAXX histone chaperone pathways promotes replication fork recovery
London: Random House (2025)
